Scilex Holding Company/DE Form 4 (Nov. 23, 2022)

Summary

A Form 4 for Sorrento Therapeutics, Inc., listed as a 10% owner of Scilex Holding Company/DE [SCLX], reporting warrant purchases on November 23, 2022. The form lists 442,829 warrants to purchase common stock, exercisable at $11.5 until 11/10/2027, bought at a weighted average price of $0.3967 per warrant. The footnote gives a price range of $0.2444 to $0.45 per warrant, inclusive. Warrants owned directly after the purchase total 4,219,604. The signature is /s/ Henry Ji, Ph.D., President, Chief Executive Officer and Chairman of the Board, Sorrento Therapeutics, Inc., dated 11/23/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Sorrento Therapeutics, Inc. (Last) (First) (Middle) 4955 DIRECTORS PLACE (Street) SAN DIEGO CA 94303 (City) (State) (Zip) | Sorrento Therapeutics, Inc. | (Last) | (First) | (Middle) | 4955 DIRECTORS PLACE | SAN DIEGO | CA | 94303 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Scilex Holding Company/DE [ SCLX ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below) | Director | X | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 11/23/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Warrants to Purchase Common Stock | $ 11.5 | 11/23/2022 | P | 442,829 | 11/10/2022 | 11/10/2027 | Common Stock | 442,829 | $ 0.3967 (1) | 4,219,604 | D
Explanation of Responses:
1. The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.2444 to $0.45 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price.
Remarks:
/s/ Henry Ji, Ph.D., President, Chief Executive Officer and Chairman of the Board, Sorrento Therapeutics, Inc. | 11/23/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_SRNE_4_filed2022-11-23_0000899243-22-036956.xml

Size

15,813 bytes

SHA-256

afff909cd0da65b8629bce91368c4ccc42636e25b8d7bfc4392bf83a87107923

Our copy

SEC_SRNE_4_filed2022-11-23_0000899243-22-036956.xml

Original

www.sec.gov